Andra AP fonden Acquires 105,000 Shares of BioMarin Pharmaceutical Inc. $BMRN

Andra AP fonden boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 282.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 142,200 shares of the biotechnology company’s stock after purchasing an additional 105,000 shares during the quarter. Andra AP fonden owned about 0.07% of BioMarin Pharmaceutical worth $7,702,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of BioMarin Pharmaceutical during the third quarter valued at about $1,047,000. Jump Financial LLC increased its stake in BioMarin Pharmaceutical by 530.3% during the second quarter. Jump Financial LLC now owns 291,217 shares of the biotechnology company’s stock valued at $16,008,000 after acquiring an additional 245,017 shares during the period. AQR Capital Management LLC raised its holdings in BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after acquiring an additional 2,654,768 shares in the last quarter. Federated Hermes Inc. raised its holdings in BioMarin Pharmaceutical by 292.6% in the 3rd quarter. Federated Hermes Inc. now owns 278,315 shares of the biotechnology company’s stock valued at $15,074,000 after acquiring an additional 207,430 shares in the last quarter. Finally, Mediolanum International Funds Ltd lifted its position in shares of BioMarin Pharmaceutical by 56.2% in the 3rd quarter. Mediolanum International Funds Ltd now owns 137,675 shares of the biotechnology company’s stock worth $7,437,000 after acquiring an additional 49,534 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $61.73 on Friday. The company has a quick ratio of 3.10, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. The firm has a market cap of $11.86 billion, a PE ratio of 34.68, a price-to-earnings-growth ratio of 0.54 and a beta of 0.26. BioMarin Pharmaceutical Inc. has a 12 month low of $50.76 and a 12 month high of $73.51. The company’s 50-day moving average price is $58.91 and its two-hundred day moving average price is $56.18.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BMRN shares. Sanford C. Bernstein boosted their price objective on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday. Leerink Partners downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Wall Street Zen cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Guggenheim reduced their price objective on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Oppenheimer lowered their target price on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 24th. Fifteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $87.71.

Insider Activity at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the sale, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This represents a 14.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.